Exoenzyme C3, Clostridium botulinum clinical trials
How each study uses exoenzyme C3, Clostridium botulinum is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
2 studies that test it; most in 2005 (1)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
BioAxone BioSciences, Inc. (2) · Vertex Pharmaceuticals Incorporated (1)
Studies
Open first, then newest update. How each study uses exoenzyme C3, Clostridium botulinum is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord InjuriesCompletedPhase 1/2Vertex Pharmaceuticals IncorporatedNCT00500812Written as CethrinHow we know
- Cethrin in Acute Cervical Spinal Cord InjuryWithdrawnPhase 2/3BioAxone BioSciences, Inc.NCT02053883Written as Cethrin (BA-210)How we know
- Safety and Efficacy of Cethrin® in Adult Subjects With Acute Cervical Spinal Cord InjuryWithdrawnPhase 2BioAxone BioSciences, Inc.NCT00610337Written as Cethrin® (BA-210)How we know